Live
Endpoints NewsActing FDA chief isn't interested in permanent roleClinical OMICsPost-Stroke Arm Immobility Improved with Spinal Cord StimulationClinical OMICsInfant Brain Development Sheds Light on Parkinson’s Link with AutismClinical OMICsAlzheimer’s Genetic Risk Loci: 16 New CandidatesEndpoints NewsActing FDA commissioner pledges to prevent political interference in rare disease meetingEndpoints NewsDimension seeks up to $750M for third life sciences fund after string of successEndpoints NewsElevance talks 'practical' AIEndpoints NewsMammalian hair, roof leaks: Novo's Catalent site in Indiana under FDA scrutiny once againFierceBiotechAutobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2BioWorldAppointments and advancements for June 4, 2026BioWorldFinancings for June 4, 2026BioWorldIn the clinic for June 4, 2026
FierceBiotech Apr 20, 2026

Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody

Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody

Original
Body unavailable. Use the original source.